FDA clears IceCure Medical's cryoablation system
The U.S. Food and Drug Administration (FDA) has granted breakthrough devic...Read more on AuntMinnie.comRelated Reading: 3 topics shaping the future of women's imaging Cryoablation comparable to surgery for kidney cancer MRI-guided cryoablation a boon for HCC patients US-guided breast cryoablation offers new treatment option SIR: Cryoablation relieves phantom limb pain (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 6, 2021 Category: Radiology Source Type: news

Obesity Tied to Increased Mortality Overall in Patients With Cancer
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2021 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pathology, Pulmonology, Radiology, Journal, Source Type: news

Getting a Prescription to Die Remains Tricky Even As Aid-in-Dying Bills Gain Momentum Across the U.S.
Linda Heim knew her dad didn’t plan to wait for the cancer to kill him. For decades, he’d lived in Montana, which they’d thought was one of the few places where terminally ill people could get a prescription to end their life. After two years of being sick, Heim’s dad got the diagnosis in 2019: stage 4 kidney cancer. His physician offered treatments that might extend his life by months. Instead, the 81-year-old asked the doctor for help dying. Heim said her parents left the appointment in their hometown of Billings with two takeaways: The legality of medically assisted death was questionable in Mont...
Source: TIME: Health - March 29, 2021 Category: Consumer Health News Authors: Katheryn Houghton / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news

Aveo boosted headcount sixfold in leadup to drug launch
Leading up to Aveo Oncology's first-ever FDA approval last week of a kidney cancer drug called Fotivda, the company has multiplied its headcount sixfold over the past year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 15, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

Aveo boosted headcount sixfold in leadup to drug launch
Leading up to Aveo Oncology's first-ever FDA approval last week of a kidney cancer drug called Fotivda, the company has multiplied its headcount sixfold over the past year. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 15, 2021 Category: American Health Authors: Don Seiffert Source Type: news

High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC High BMI Tied to Better Overall Survival in Immune Checkpoint Inhibitor-Treated Metastatic RCC
In patients with metastatic renal cell carcinoma treated with PD-1/PD-L1-based immune checkpoint inhibitors (ICIs), higher body mass index was associated with improved overall survival in a database study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mayo Clinic Q & amp;A podcast: Kidney cancer often found by accident
Your kidneys remove waste from your blood and regulate a healthy balance between water, sodium and minerals in your bloodstream. "Kidneys filter intoxicants, drugs and waste products out of your blood," says Dr. Scott Cheney, a Mayo Clinic urologic surgeon. "We would actually die within about a week without having good kidney function." Poor kidney [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - March 15, 2021 Category: Research Source Type: news

FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson
CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ... (Source: McKesson News)
Source: McKesson News - March 12, 2021 Category: Information Technology Source Type: news

Dana-Farber research leads to better understanding of the immune system in kidney cancer
(Dana-Farber Cancer Institute) In two new studies published today in Cancer Cell, researchers from Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard used the emerging technology of single-cell RNA sequencing to draw a clearer picture of how kidney tumors' microenvironments change in response to immunotherapy. The researchers believe that this work points to potential targets for new drug therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 10, 2021 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news

Aveo finally earns approval for kidney cancer drug
More than 14 years after Boston-based Aveo Oncology licensed an experimental cancer drug from a Japanese biotech, the company announced Wednesday that the drug has earned approval by the U.S. Food and Drug Administration to treat kidney cancer, ending a long and tumultuous journey. The pill has the generic name of tivozanib, and will be marketed under the brand name, Fotivda, for use by patients with relapsed or refractory advanced renal cell carcinoma who have tried at least two other drugs previously. The… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2021 Category: Biotechnology Authors: Don Seiffert Source Type: news

FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 10, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Fotivda (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
BOSTON--(BUSINESS WIRE) March 10, 2021 -- AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved Fotivda (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 10, 2021 Category: Drugs & Pharmacology Source Type: news

New hope for advanced kidney cancer patients
Renal cell carcinoma, the most common form of kidney cancer, can quickly spread through the body and if diagnosed at a late stage it is usually inoperable, with patients given only a year to live. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2021 Category: Consumer Health News Source Type: news

Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
WEDNESDAY, March 3, 2021 -- For patients with previously untreated advanced renal cell carcinoma, nivolumab plus cabozantinib has significant benefits over sunitinib with respect to progression-free and overall survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 3, 2021 Category: Pharmaceuticals Source Type: news

Oncotarget: Identification intermediate-risk subgroups in metastatic clear-cell renal cell carcinoma
(Impact Journals LLC) " Elevated PLT count seems to identify a subgroup of patients with poor outcome in the IMDC intermediate-risk population with ccRCC " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2021 Category: Cancer & Oncology Source Type: news

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2021 Category: Pharmaceuticals Source Type: news

Cabozantinib may be cost effective in advanced renal cell carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2021 Category: Drugs & Pharmacology Source Type: news

FDA D.I.S.C.O. Burst Edition: Enhertu (fam-trastuzumab deruxtecan-nxki ) and combination of Opdivo (nivolumab) and Cabometyx (cabozantinib)
Enhertu (fam-trastuzumab deruxtecan-nxki) for locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma and received a prior trastuzumab-based regimen. Combination of Opdivo (nivolumab) + Cabometyx (cabozantinib) as first-line treatment for advanced renal cell carcinoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

CT-guided renal ablation is safe for treating cancer in obese patients
CT-guided renal ablation is a safe and effective alternative to nephrectom...Read more on AuntMinnie.comRelated Reading: AI could help radiologists better detect kidney cancer Cryoablation comparable to surgery for kidney cancer Do more CT scans lead to more kidney surgeries? SPECT/CT can solve renal cell carcinoma diagnosis conundrum (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news

Drug Improves Survival for Rare, Deadly Kidney Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 22, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, News, Source Type: news

Cabozantinib Improves Survival for Rare, Deadly Kidney Cancer
MONDAY, Feb. 22, 2021 -- The drug cabozantinib is more effective than two similar drugs, as well as the current standard treatment, in extending the lives of patients with a rare and deadly type of kidney cancer, according to a new study. The... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 22, 2021 Category: General Medicine Source Type: news

Drug Improves Survival for Rare, Deadly Kidney Cancer
Title: Drug Improves Survival for Rare, Deadly Kidney CancerCategory: Health NewsCreated: 2/22/2021 12:00:00 AMLast Editorial Review: 2/22/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 22, 2021 Category: Cancer & Oncology Source Type: news

Lenvatinib Plus Pembrolizumab Tops Sunitinib in Advanced RCC
FRIDAY, Feb. 19, 2021 -- For first-line treatment of advanced renal cell carcinoma, progression-free and overall survival are significantly longer with lenvatinib plus pembrolizumab versus sunitinib, according to a study published online Feb. 13 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2021 Category: Pharmaceuticals Source Type: news

Combo Shows'Impressive' Survival Results in First-Line RCC Combo Shows'Impressive' Survival Results in First-Line RCC
The combination of lenvatinib and pembrolizumab outperformed sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC) in the CLEAR trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

"Silent" Mutation Linked to Worse Kidney Cancer Outcome
A synonymous mutation in the tumor suppressor gene BAP1 can result in loss of function of the protein without altering its amino acid sequence. (Source: The Scientist)
Source: The Scientist - February 17, 2021 Category: Science Tags: News & Opinion Source Type: news

Cabozantinib Prolongs PFS in Papillary Renal Cell Carcinoma
WEDNESDAY, Feb. 17, 2021 -- For adults with papillary renal cell carcinoma (PRCC), the dual vascular endothelial growth factor (VEGF)-MET (hepatocyte growth factor receptor) inhibitor cabozantinib improves progression-free survival (PFS), according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 17, 2021 Category: Pharmaceuticals Source Type: news

Cabozantinib Could Be New Standard for Papillary RCC Cabozantinib Could Be New Standard for Papillary RCC
Cabozantinib outperforms the current standard of care for renal cell carcinoma (RCC), according to results from the Southwest Oncology Group 1500 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Kidney cancer: A cluster of veins on your right testicle could be an early risk indicator
KIDNEY cancer: One in 34 males and one in 64 females will be diagnosed with kidney cancer in their lifetime warns Cancer Research. For men, noticing a cluster of veins on your right testicle could be an early sign. (Source: Daily Express - Health)
Source: Daily Express - Health - February 16, 2021 Category: Consumer Health News Source Type: news

MSK physician shares kidney cancer research at annual ASCO GU Symposium
(Memorial Sloan Kettering Cancer Center) Memorial Sloan Kettering's Robert Motzer presented positive data from a phase III randomized study that assessed two different treatment combinations as first-line therapies that may benefit people with advanced kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 16, 2021 Category: International Medicine & Public Health Source Type: news

Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand
In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug is launched at a MRP that is approximately 96 per cent lower than the MRP (maximum retail price) compared to the innovator brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5 mg) per month". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 16, 2021 Category: Pharmaceuticals Source Type: news

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer
(Dana-Farber Cancer Institute) Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2021 Category: Cancer & Oncology Source Type: news

Cabozantinib most effective treatment for metastatic papillary kidney cancer
(SWOG) In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 13, 2021 Category: Cancer & Oncology Source Type: news

Association of Hepatitis C Infection and Risk of Kidney Cancer Association of Hepatitis C Infection and Risk of Kidney Cancer
Do patients with hepatitis C have a significantly higher risk of developing kidney cancer?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Which Patients With Kidney Cancer Are Likely to Respond to ICI? Which Patients With Kidney Cancer Are Likely to Respond to ICI?
Several factors in patients with clear cell renal cell carcinoma are associated with a diminished response to immune checkpoint inhibition (ICI).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 5, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cholesterol starvation kills lymphoma cells
(Northwestern University) Scientists have developed a novel therapy to trick cancer cells into gobbling up what they think is their favorite food - cholesterol -- which actually triggers their destruction. What appears to them as a cholesterol-loaded particle is actually a synthetic nanoparticle that binds to the cancer cells and starves them to death. The study was in lymphoma cells but could be effective in ovarian and kidney cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2021 Category: Cancer & Oncology Source Type: news

FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 22, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) in Combination with Cabometyx (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE) January 22, 2021-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with Cabometyx... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 22, 2021 Category: Drugs & Pharmacology Source Type: news

Researchers uncover potentially promising therapeutic combination for renal cell carcinoma
(Beth Israel Deaconess Medical Center) Investigators have demonstrated that ACE2 expression is a good prognostic factor in RCC, that loss of ACE2 mediates resistance to classical treatments, and that in preclinical models, treatment with a drug that is downstream of ACE2 can improve tumor responses in RCC and significantly prolong survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 20, 2021 Category: Cancer & Oncology Source Type: news

A metabolic shift into kidney cancer
(Source: ScienceNOW)
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Wong, W. Tags: twis Source Type: news

Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer
Understanding the mechanisms of the Warburg shift to aerobic glycolysis is critical to defining the metabolic basis of cancer. Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an aggressive cancer characterized by biallelic inactivation of the gene encoding the Krebs cycle enzyme fumarate hydratase, an early shift to aerobic glycolysis, and rapid metastasis. We observed impairment of the mitochondrial respiratory chain in tumors from patients with HLRCC. Biochemical and transcriptomic analyses revealed that respiratory chain dysfunction in the tumors was due to loss of expression of mitochondrial DNA (mtDNA)&n...
Source: Signal Transduction Knowledge Environment - January 5, 2021 Category: Science Authors: Crooks, D. R., Maio, N., Lang, M., Ricketts, C. J., Vocke, C. D., Gurram, S., Turan, S., Kim, Y.-Y., Cawthon, G. M., Sohelian, F., De Val, N., Pfeiffer, R. M., Jailwala, P., Tandon, M., Tran, B., Fan, T. W.- M., Lane, A. N., Ried, T., Wangsa, D., Malayeri Tags: STKE Research Articles Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 4, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Peninsula biotech Calithera cuts a third of jobs after kidney cancer trial flop
Calithera Biosciences Inc. shed nearly half of its value and will cut about 30 jobs after a mid-stage clinical trial of its marquee drug failed in kidney cancer patients. The South San Francisco company (NASDAQ: CALA) said the job cuts represent 35% of its workforce. The bulk of the job losses would be among those prepping for a potential commercial launch of the drug, called telaglenastat or CB-839. The company's 444-person Phase II study found that advanced or m etastatic renal cell carcinoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Browns fan Tom Seipel, battling kidney cancer and in hospice, gets one ‘last-ditch party,’ thanks to his fell
Tom Seipel doesn't know how much longer he has, but he'll get to go to Sunday's Browns-Steelers game thanks to the help of Browns fans... (Source: Reuters: Health)
Source: Reuters: Health - January 3, 2021 Category: Consumer Health News Source Type: news

Cancers in U.S. Teens, Young Adults Have Risen by 30% Since 1970s: Study
  THURSDAY, Dec. 3, 2020 -- Cancer cases among U.S. teens and young adults have shot up 30% since the 1970s, new research reveals. Kidney cancer has risen at the greatest rate, increasing more than threefold among young men and women,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 3, 2020 Category: General Medicine Source Type: news

Cancer cases are rising in adolescents and young adults
(Penn State) Cancer cases in adolescents and young adults have risen by 30% during the last four decades, with kidney cancer rising at the greatest rate, according to researchers at Penn State College of Medicine. The team said further research into screening, diagnosis and treatment are needed to address the growing trend in this age group. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2020 Category: Cancer & Oncology Source Type: news

$11M NIH grant will fund biomedical research at University of Delaware
(University of Delaware) The National Institutes of Health has renewed a Center of Biomedical Research Excellence (COBRE) grant, worth more than $11 million. The University of Delaware Center is focused on discovery of new molecules that can be used to study and treat diseases such as breast cancer, renal cancer, Crohn's disease, tuberculosis and Legionnaires disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 30, 2020 Category: Biology Source Type: news

Cancer Prevention and Screening for Older Adults Cancer Prevention and Screening for Older Adults
This review addresses special considerations regarding prevention and early identification of lung, colorectal, bladder, and kidney cancer for adults aged 65 and older.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Immunotherapy side effect could be a positive sign for kidney cancer patients
(UT Southwestern Medical Center) An autoimmune side effect of immune checkpoint inhibitor (ICI) drugs could signal improved control of kidney cancer, according to a new study by researchers in UT Southwestern's Kidney Cancer Program (KCP). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 2, 2020 Category: International Medicine & Public Health Source Type: news

UC studies tobacco use, cancer connection
(University of Cincinnati) Researchers at the University of Cincinnati have identified new clues into ways tobacco use impacts patients with kidney cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2020 Category: International Medicine & Public Health Source Type: news